Emergent BioSolutions Reports Financial Results for First Quarter 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Emergent BioSolutions (EBS) Tops Q1 EPS by 41c; Guides Q2 Revs Lower
April 29, 2021 4:15 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q1 EPS of $1.53, $0.41 better than the analyst estimate of $1.12. Revenue for the quarter came in at $343 million versus the consensus estimate of $358.47 million.
GUIDANCE:
Emergent BioSolutions sees Q2 2021 revenue of $370-430 million, versus the consensus of... More
